Lisocabtagene maraleucel
JCAR017-FOL-001
Phase 2 small_molecule active
Quick answer
Lisocabtagene maraleucel for Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL) is a Phase 2 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active